StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
PHH2.F$210.00-0.94%
Fair $210.00+0.0%

PHH2.F

Paul Hartmann AG

Healthcare / Medical Instruments & SuppliesFrankfurt

$210.00

-2.00 (-0.94%)

Fairly Valued+0.0%Fair Value $210.00Fund rank 29/100 · Data gapFallback financials|
SA 47/C
F-Score: 4/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 33% · confianza 22%

FCF escenarios

weak_data · normalized FCF $60.1M · quality 49.3/100

Data gap 29/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 26/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

47/100

C

Piotroski

4/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · PHH2.FLocal privado en este navegador · Paul Hartmann AG
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$746M

P/E

12.2x

↓

EV/EBITDA

4.0x

↓

ROE

5.2%

↑

Gross Margin

60.4%

↑

Debt/Equity

0.30

↑
52-Week Range$210
$200$254

TradingView lightweight chart

PHH2.F price, volumen y niveles de valoración

Último $210.00Periodo +27.3%
Fair value: $210.00

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+2.0%

FCF CAGR

—

FCF margin

1.2%

FCF / Net income

0.46x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $2.45B · net income $61.2M · FCF $28.4M

2022-FY → 2025-FY

Gross margin

60.4%+3.7% pts

Operating margin

4.0%+2.6% pts

Net margin

2.5%+0.9% pts

FCF margin

1.2%+6.3% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$2.45B$2.45B$2.41B$2.35B$2.31B
Net Income$61.2M$61.2M$108.5M$28.4M$36.1M
EBITDA$234.8M$234.8M$248.8M$167.8M$167.3M
EPS17.2317.2330.538.0010.18
Gross Margin60.4%60.4%59.8%56.0%56.7%
Operating Margin4.0%4.0%4.7%1.4%1.3%
Net Margin2.5%2.5%4.5%1.2%1.6%
Balance Sheet
Debt/Equity0.300.300.250.230.23
Current Ratio2.222.22———
Cash Flow
Free Cash Flow$28.4M$28.4M$60.1M$117.7M$-119.2M
Returns
ROE5.2%5.2%9.4%2.7%3.4%
Valuation
P/E12.2012.207.2425.0021.81
EV/EBITDA4.004.003.674.825.57
P/B0.630.630.680.670.73
Growth & Yield
Revenue Growth1.7%1.7%2.3%1.8%—
EPS Growth-43.6%-43.6%281.6%-21.4%—
Dividend Yield3.8%3.8%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

2.6%

fácil

EPS terminal req.

$18.63

Spread vs growth

-46.2%

5Y implied EPS CAGR

5.5%

razonable

EPS terminal req.

$22.55

Spread vs growth

-49.1%

10Y implied EPS CAGR

7.7%

razonable

EPS terminal req.

$36.31

Spread vs growth

-51.3%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -11.9%

Total return

-11.9%

Start / end P/E

8.2x → 12.2x

EPS bridge

30.53 → 17.23

Residual

-21.5%

EPS growth-43.6%
Multiple rerating+49.4%
Dividend+3.8%
Residual / FX / buybacks / cross-term-21.5%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.